Global Survey from World Lupus Federation Finds Nearly Half of People with Lupus Report Kidney Involvement
New data highlights urgent need for improved education and diagnosis of lupus nephritis (lupus-related kidney disease), a serious complication of lupus
WASHINGTON, May 6, 2025 /PRNewswire/ -- A global survey conducted by the World Lupus Federation reveals that 47% of people living with lupus report kidney involvement, which leads to a critical and under-recognized complication known as lupus nephritis (lupus-related kidney disease). More than 43% of respondents reported having little or no knowledge about lupus nephritis, however, 85% of respondents also reported experiencing one or more symptoms associated with lupus nephritis. The survey findings underscore significant gaps in the understanding, diagnosis, and treatment of lupus nephritis, a potentially life-threatening condition that disproportionately affects people during their most active years of life.
Lupus nephritis occurs when the immune system mistakenly attacks the kidneys, leading to inflammation and possibly to long-term organ damage, including kidney failure, if left untreated. Although most cases of lupus nephritis begin within five years of a lupus diagnosis, nearly one in five survey respondents who self-report having symptoms of kidney involvement have not been told by a doctor they have lupus nephritis.
In its early stages, the symptoms of lupus nephritis can go unnoticed. More than half of the respondents reported little or no knowledge of common symptoms of lupus nephritis (53%), when it is important to be screened (54%), and what tests are done to screen for lupus nephritis (57%). Symptoms of lupus nephritis include fluid retention leading to weight gain, swelling, an increase in urination (especially at night), blood in the urine, foamy appearance of the urine, and high blood pressure.
"These findings reveal a troubling reality—many people with lupus are living with kidney complications they don't fully understand or even know they have," said Louise Vetter, President & CEO of the Lupus Foundation of America. "Early diagnosis and access to appropriate treatment are essential for protecting kidney health and preventing long-term damage. We must act urgently to close these knowledge gaps and improve education of common symptoms and proper monitoring of the kidneys, in addition to improved care across the globe. As we recognize World Lupus Day on May 10, this is a moment to rally together, raise our voices, and fight for better outcomes for everyone living with lupus."
Additional key findings include:
More than 3,260 people with lupus from 84 countries completed the 25-question survey administered in March 2025. The World Lupus Federation is releasing these survey results in the lead-up to World Lupus Day on May 10 to spotlight the urgent need for greater awareness, education, improved screening, and timely treatment of lupus and lupus nephritis.
The World Lupus Federation urges individuals, organizations, and healthcare providers worldwide to use this data to inform lupus education and awareness efforts, and to share facts about lupus, including from this survey, and raise awareness using the official World Lupus Day Toolkit.
For further survey details, view the topline visual summary and detailed survey results.
The World Lupus Federation (WLF) is a coalition of more than 200 lupus patient organizations, united to improve the quality of life for the approximately 5 million people around the world who are affected by lupus. Through coordinated efforts among its members, the Federation works to expand global initiatives that create greater awareness and understanding of lupus, provide education and services to people living with the disease and advocate on their behalf. The Lupus Foundation of America (LFA) co-founded the WLF with Lupus Europe in 2015 and the LFA currently serves as the Secretariat of the Federation.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Korea Herald
3 hours ago
- Korea Herald
Philips Future Health Index 2025: Delayed care and lost clinical time call for accelerated AI adoption in APAC
SINGAPORE, June 12, 2025 /PRNewswire/ -- Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today released the Asia Pacific (APAC) findings from its 10th annual Future Health Index (FHI) report, the largest global healthcare survey of its kind. The report draws insights on key concerns from healthcare professionals and patients in 16 countries, including Australia, Indonesia, and South Korea. Findings show that despite strong optimism about artificial intelligence's (AI) potential to ease pressure on APAC's healthcare systems, trust and implementation concerns persist. "The need for AI has never been greater. Our survey shows that patients are anxiously waiting more than a month for specialist care, while some healthcare professionals are losing about four working weeks of clinical time a year due to incomplete patient data," said Jasper Westerink, Senior Vice President and Representative Director of Philips Japan and Acting Managing Director of Philips APAC. "There is a clear role for AI to help clinicians act faster, make better decisions, and anticipate patient needs earlier as we strive to deliver better care for more people." Worsening patient outcomes because of care delays call for accelerated AI adoption About two in three patients (66%) surveyed in APAC are waiting nearly one and a half months to see a specialist doctor, with an average waiting time of 47 days. Generally, one in three patients (33%) in APAC report that their health has deteriorated due to delays in seeing a doctor, with one in four (25%) ultimately going to the hospital as a result of long waiting times. AI has the potential to transform care delivery and significantly improve patient outcomes across APAC. Workforce challenge and data burdens call for AI relief Three in four healthcare professionals (76%) in APAC report losing valuable clinical time due to incomplete or inaccessible patient data, with close to one-third (31%) of these losing over 45 minutes per shift, adding up to 23 full days a year lost by each professional. Similarly, two in five (39%) clinicians say they are now spending less time with patients and more time on administrative tasks than they were five years ago. These exacerbate the workforce challenge experienced by healthcare professionals in APAC, as estimated by the World Health Organization. The shortage of health workers in Southeast Asia alone will be 6.9 million respectively in 2030, nearly 40% of the global shortage burden. [1] About 300 healthcare professionals surveyed shared the following concerns if AI is not implemented: Addressing AI concerns from HCPs and patients crucial for widespread adoption A majority of healthcare professionals (81%) in APAC are involved in developing new technology at their organizations. However, 39% believe that the new technologies developed are not catered to their needs. Concerns around accountability persist, with 71% sharing concerns about the legal liability for AI usage, while 66% worry that potential data biases in AI applications could widen disparities in health outcomes. Among patients, a majority (75%) welcome the increased use of technology if it improves access to care and benefits them. Around half are concerned that it could reduce face-to-face time with their doctors (51%) and are worried about data security when new technologies are introduced in healthcare (54%). Trust key to transforming healthcare in APAC For the majority of healthcare professionals surveyed (84%) building trust in AI has to involve support with guidelines, issues and liability. In addition, healthcare professionals cite the development of evidence-based, transparent, and monitored AI solutions (72%), followed by reassurance on data security issues, with 51% of healthcare professionals seeking clarity in this area. For patients, about three in four (74%) welcome the use of more technology in healthcare if it helps make it easier to see a healthcare professional and if it helps improve care for patients like themselves (75%). Healthcare professionals play a key role in building trust between patients and AI. Majority of patients (86%) would feel more comfortable with AI in healthcare if hearing about it from their doctors, indicating that doctors are a trusted source of information about such technologies. "It's essential to foster trust of AI-powered technologies among healthcare professionals and patients," said Jasper. "This will enable widespread adoption and effective implementation. Industry-wide collaboration will help us address trust gaps to unlock AI's full potential, enabling responsible, inclusive integration across APAC's healthcare systems." For details on the Future Health Index methodology and to access the full Future Health Index 2025 report, visit Future Health Index | Philips. About the Future Health Index 2025 The Future Health Index is the largest global survey of its kind, analyzing the priorities and perspectives of healthcare professionals and patients across multiple countries. The Future Health Index 2025 investigates how innovative technologies, particularly AI, can empower healthcare professionals to deliver better care to more people. For more information, or to download the full FHI 2025 Global Report, visit About Royal Philips Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and well-being through meaningful innovation. Philips' patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, ultrasound, image-guided therapy, monitoring and enterprise informatics, as well as in personal health. Philips generated 2024 sales of EUR 18 billion and employs approximately 67,200 employees with sales and services in more than 100 countries. News about Philips can be found at
Korea Herald
2 days ago
- Korea Herald
Wingderm® Strengthens Presence in Asia at IMCAS Asia 2025
BEIJING, June 10, 2025 /PRNewswire/ -- From June 6 to 8, 2025, IMCAS Asia was successfully held in Bangkok, Thailand. As one of the world's leading medical aesthetic events, IMCAS Asia brought together the latest developments and trends in the Asian medical aesthetic market. Wingderm® once again showcased its innovative medical aesthetic solutions. Focusing on Asia's Growing Medical Aesthetic Market The Asian market includes both mature economies, such as China, Japan, and South Korea, as well as rapidly growing Southeast Asian countries. This makes the region a crucial player in the global medical aesthetic industry. IMCAS Asia is not only a platform for sharing knowledge, but also offers Wingderm® a valuable opportunity to better understand practitioner perspectives and stay aligned with market trends, supporting product upgrades and strategic expansion. Tech Meets Trust: Driving Mutual Growth through Innovation At IMCAS Asia, Wingderm® presented a series of advanced medical aesthetic devices, including Mesoskin for non-invasive delivery, Lasermach for fast and comfortable laser hair removal, and Renuva, a device powered by 1550nm non-ablative fractional laser for skin resurfacing. Our success at the event was thanks to the support of our local distributor in Thailand. We will continue this close partnership for mutual benefit. Next Stop: TAS 2025 in Las Vegas Driven by technology and innovation, Wingderm® is always looking for new ways to apply our technologies and enhance user experiences. Through industry events, we share our latest advancements and strengthen connections with industry professionals around the world. Wingderm® will be at booth 712 during TAS 2025, held from June 27 to 29 in Las Vegas. Please visit us there！ About Wingderm® Wingderm® since its establishment in 2016, with the aim of "Aesthetics&Technology, Easy to Achieve", provides leading and reliable intelligent photoelectric medical aesthetic devices, which have been exported to more than 80 countries, with over 25,000 units installed, recognized for safety and effectiveness by experts and beauty seekers.
Korea Herald
5 days ago
- Korea Herald
HIRONIC Successfully Hosts First Asia Innovation Summit 2025
SEOUL, South Korea, June 7, 2025 /PRNewswire/ -- HIRONIC, a global leader in non-invasive medical aesthetic technology, has successfully hosted its inaugural 'HIRONIC Innovation Summit 2025. Asia Edition' in Bangkok, Thailand on June 5th. The event brought together approximately 100 medical professionals and medical distribution industry representatives from South Korea, Thailand, Vietnam, Malaysia, Indonesia, Myanmar, and other countries. Across four in-depth clinical sessions, speakers presented the latest approaches to skin rejuvenation, covering multi-layered face and body lifting, advanced scar treatment, and next-generation needle-free drug delivery technologies. One of the keynote lectures was delivered by Dr. Wonkyu Hong, Director and dermatologist at Human Dermatology Clinic and Executive Director of the Human Clinical Trial Center in South Korea. Dr. Hong explored the rapidly evolving role of needle-free technology in aesthetic medicine, sharing his clinical experience while emphasizing both its therapeutic advantages and its significant market growth potential driven by increasing patient demand for non-invasive rejuvenation solutions. Dr. Thitikom Limrattanamekha, founder and CEO of Optima Aesthetics in Thailand and an experienced laser specialist in scar treatment, skin quality improvement, and pigmentation management, shared his expertise on combining pico laser and RF microneedling to achieve highly effective outcomes in complex scarring cases. His presentation highlighted how advanced combination protocols are reshaping non-surgical treatment approaches and expanding therapeutic options for physicians worldwide. The symposium also provided a platform to showcase the clinical advancements and growing market relevance of HIRONIC's flagship export technologies, including New Doublo™, PICOHI™, and the latest needle-free delivery system Synerjet PRO™. Sasha Borovtsova, Head of Global Marketing Office at HIRONIC, stated, "This summit not only showcased the real-world clinical applications of our technologies but also underscored the accelerating global demand for safer, more versatile, and highly effective aesthetic solutions. As innovation continues to drive market growth, HIRONIC remains committed to advancing technology and strengthening global expertise and partnerships through events like the HIRONIC Innovation Summit." Headquartered in South Korea, HIRONIC is a leading global manufacturer of medical aesthetic devices, specializing in HIFU, RF, laser, and needle-free technologies. With a presence in over 80 countries, HIRONIC has introduced iconic devices such as Doublo™, Doublo Gold™, and New Doublo 2.0™ to the international market.
